Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Narrative (Details)

v3.22.4
Revenue Recognition - Narrative (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Revenue from Contract with Customer [Abstract]      
Number of operating segments | segment 2    
Pharma contract liability, revenue recognized $ 5.2 $ 4.4 $ 2.3
Amortization of contract commissions $ 0.9 $ 1.1 $ 0.8